2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow relebactam: new trials by email Literature Review of relebactam trials Research Report on relebactam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004) Relebactam 250 mg, Relebactam 125 mg, Imipenem/cilastatin - Intra-abdominal Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 351 | 2012-06-01 | 2019-06-10 |
| Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003) Relebactam 250 mg, Relebactam 125 mg, imipenem/cilastatin 500 mg - Urinary Tract Infections, Pyelonephritis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 302 | 2012-05-16 | 2019-05-24 |
Intraabdominal Infections (1) · Pyelonephritis (1) · Urinary Tract Infections (1) · Urologic Diseases (1)